HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

ENOV

Enovis Corporation (NYSE)

Healthcare — Medical Devices

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Strong Buy 1.4 / 5 10 analysts
$20.04
$-0.66 (-3.19%)
Target: $42.30 (111.1%)
Sign in to add ENOV to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$1.15B
P/E Ratio (TTM)-
Forward P/E4.92
EPS (TTM)$-19.89
Dividend Yield-
Profit Margin-49.91%
Revenue Growth5.40%
ROE-55.35%
Debt/Equity95.34
Recommendation Strong Buy 1.4
Analyst Target$42.30
Analysts10
Indexes NYSE

Technical Indicators

RSI (14)40.2
Beta1.49
SMA 20-
SMA 40-
52-Week High$36.82
52-Week Low$19.14
50-Day Avg$23.31
200-Day Avg$25.97
Avg Volume$1.09M
Volume$1.50M

Performance Analysis

NEUTRAL

ENOV presents a mixed picture with both positive and negative indicators.

+ Trading near its 52-week low ($19.14), which could present a value opportunity.
~ RSI at 40.2 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
~ Modest revenue growth of 5.4% year-over-year.
- Operating at a loss with -49.9% margin.
+ Wall Street consensus is "Strong Buy" from 10 analysts.
+ Average analyst target of $42.30 implies 111.1% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:08 UTC

Back to Screener Export Report